Mounjaro Injection FDA Approval: Key Dates, Indications & Safety

Estimated reading time: 14 min

Key Takeaways

• Mounjaro injection received FDA approval on May 13, 2022, for type 2 diabetes in adults.
• It is not FDA-approved for weight loss or obesity treatment as of January 2025.
• Mounjaro and Zepbound share the same active ingredient (tirzepatide) but have different FDA approvals.
• FDA-approved Mounjaro injection dosages range from 2.5 mg to 15 mg, administered once weekly.
• Mounjaro carries boxed warnings regarding thyroid tumors and other safety considerations.

Table of Contents

• Section 1: Mounjaro Injection FDA Approval Timeline
• Section 2: Approved Indications and Uses
• Section 3: Mounjaro vs. Zepbound — Same Drug, Different Approvals
• Section 4: Dosage, Scheduling, and Administration
• Section 5: Mechanism of Action and Clinical Evidence
• Section 6: FDA Safety Warnings and Label Updates
• Conclusion
• FAQ

Section 1: Mounjaro Injection FDA Approval Timeline

FDA Approval Date and Process

Mounjaro injection (tirzepatide) received FDA approval on May 13, 2022. This marked a significant milestone in diabetes care. The approval followed a systematic review of clinical evidence demonstrating Mounjaro’s effectiveness and safety in adults with type 2 diabetes.

The FDA approval process for Mounjaro was rigorous and multifaceted, reflecting the agency’s high standards for both efficacy and safety. Eli Lilly and Company submitted the New Drug Application (NDA), which included comprehensive data from both preclinical (laboratory and animal) and clinical (human) studies. The FDA’s review involved endocrinology experts, statisticians, and pharmacologists, who meticulously analyzed the submitted data. The final approval was based not only on the primary clinical trial outcomes but also on a detailed risk-benefit assessment, post-approval commitments, and a proposed plan for ongoing monitoring of the medication’s use in the real world.

Regulatory Milestones

• 2021–2022: Submission and review of Mounjaro’s new drug application (NDA) by Eli Lilly and Company. The NDA included results from nine phase 3 clinical trials known as the SURPASS program.
• May 13, 2022: FDA grants approval for Mounjaro injection as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. This approval came with required Risk Evaluation and Mitigation Strategies (REMS) and post-marketing commitments for further research, particularly in pediatric populations and long-term outcomes.
• Post-approval: Ongoing monitoring, with mandatory postmarket studies and updates to labeling as new safety data emerge. The FDA also required the sponsor to initiate a pregnancy exposure registry and conduct additional studies on medication use in special populations.

Significance of FDA Approval

The FDA approval of Mounjaro injection was based on robust evidence from nine clinical trials, involving thousands of adult participants. These studies confirmed its ability to help lower blood sugar (A1C) and, in many patients, promote weight loss as a secondary effect. However, it’s important to note that while many individuals using Mounjaro see weight changes, the FDA-approved use is for type 2 diabetes management—not weight loss.

In clinical practice, the approval of Mounjaro expanded the therapeutic options for adults with type 2 diabetes, especially those who had not achieved glycemic targets with existing treatments. Mounjaro’s dual GIP/GLP-1 receptor agonist action set it apart from previous medications, offering new hope for patients struggling with blood sugar control.

For those starting or tracking their Mounjaro journey, logging your medication and progress can provide clarity. Apps like Trimm are designed to help users track injections, monitor side effects, and visualize their progress throughout a GLP-1 medication journey. Keeping a record of injection dates, doses, and any side effects can help both you and your healthcare provider assess how well the medication is working and identify any patterns that may need attention.

Section 2: Approved Indications and Uses

FDA-Approved Use: Type 2 Diabetes in Adults

Mounjaro injection is FDA-approved as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes. It is not indicated for use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. The FDA does not recommend Mounjaro as a first-line therapy; it is typically prescribed when other diabetes medications are insufficient or not tolerated.

• Population: Adults (18 and over) with type 2 diabetes. This includes individuals who have not achieved adequate glycemic control with metformin, sulfonylureas, SGLT2 inhibitors, or insulin, or those who cannot tolerate these medications.
• Not approved for: Children, adolescents (under 18), type 1 diabetes, or as a standalone weight loss medication. The effects, safety, and efficacy in these populations are still under investigation in ongoing clinical trials.

Mounjaro’s approval as an adjunct to diet and exercise highlights the importance of a holistic approach to diabetes care. Medications alone are rarely sufficient for optimal outcomes. Patients are encouraged to work with their healthcare team to address nutrition, physical activity, and lifestyle modifications in parallel with pharmacologic treatment.

Is Mounjaro FDA Approved for Weight Loss?

A common question is: is Mounjaro FDA approved for weight loss? As of January 2025, the answer is no. Although clinical trials demonstrated weight loss in many adults using Mounjaro for type 2 diabetes, the FDA has not approved it for obesity or weight management. If you’re specifically seeking an FDA-approved weight loss medication with tirzepatide, you may want to look into Zepbound, which was approved for chronic weight management in adults in November 2023 (see Section 3 for details).

It’s important to acknowledge that weight and health are deeply personal and multifactorial. While Mounjaro may be associated with weight loss for some, it is not a substitute for individualized medical care or a comprehensive weight management plan. Medical decisions regarding the use of any medication for weight should always be made in partnership with a healthcare provider, considering overall health, medical history, and personal goals.

Current Labeling and Restrictions

The FDA label for Mounjaro injection restricts its use to adults and requires prescribing professionals to consider individual patient risks, medical history, and other medications. The FDA has also mandated postmarket studies, including a pediatric study due by 2027, to further evaluate safety in younger populations.

• Pediatric Use: Mounjaro is not approved for use in children or adolescents. The FDA has required Eli Lilly to conduct pediatric clinical trials, with results expected by 2027, to determine safety and efficacy in these age groups.
• Contraindications: Mounjaro should not be used in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Other Considerations: Prescribers are instructed to review a patient’s full medical and medication history to avoid interactions or heightened risk of adverse effects. For example, caution is advised in patients with a history of pancreatitis or severe gastrointestinal disease.

Section 3: Mounjaro vs. Zepbound — Same Drug, Different Approvals

What’s the Difference Between Mounjaro and Zepbound?

Mounjaro and Zepbound both contain the same active ingredient: tirzepatide. However, they have different FDA-approved indications and branding. Understanding these distinctions is crucial for patients and healthcare providers.

• Mounjaro: FDA-approved for type 2 diabetes in adults (May 2022). It is prescribed to improve glycemic control and is typically covered by insurance plans for those with a documented diagnosis of type 2 diabetes.
• Zepbound: FDA-approved for chronic weight management (obesity/overweight with weight-related conditions) in adults (November 2023). Zepbound can be prescribed for adults with a body mass index (BMI) of 30 or higher, or 27 or higher with at least one weight-related comorbidity (such as hypertension, dyslipidemia, or obstructive sleep apnea).

Why Separate Approvals?

The FDA reviews drug applications for each intended use. Mounjaro’s clinical trials focused on glycemic control in diabetes, while Zepbound underwent separate studies specifically for weight loss and obesity management. This means that, even though they are chemically identical, insurance coverage, prescribing guidelines, and safety information may differ based on the brand and approved indication.

For example, if a patient without diabetes is seeking tirzepatide for weight management, their healthcare provider would prescribe Zepbound, not Mounjaro. Conversely, for an adult with type 2 diabetes, Mounjaro is typically the indicated product. This distinction is important not only for clinical appropriateness but also for insurance reimbursement and regulatory compliance.

Coverage and Prescribing Considerations

• Insurance: Coverage for Mounjaro is typically tied to a diagnosis of type 2 diabetes; Zepbound is covered for weight management in eligible adults. Some insurance plans may require prior authorization, documentation of previous weight loss attempts, or a prescription from a specialist.
• Labeling: The FDA-approved label for each medication differs in its instructions, warnings, and patient eligibility criteria. These differences can affect what monitoring is required, how often follow-up visits are needed, and what information must be communicated to patients.

For patients and clinicians, it’s crucial to follow the approved labeling and guidelines for each medication. Using a medication outside its approved indication (“off-label”) is a decision that should only be made with full awareness of the risks, benefits, and legal considerations, and always in partnership with a healthcare provider.

If you’re interested in tracking either Mounjaro or Zepbound injections, Trimm supports both. For more on how to log injections, see our guide on how to log GLP-1 injections. This can help you stay organized, remember injection dates, and communicate more effectively with your care team.

Section 4: Dosage, Scheduling, and Administration

FDA-Approved Dosage Levels

The FDA has approved Mounjaro injection in a range of dose strengths from 2.5 mg to 15 mg, administered once weekly. The drug is supplied in prefilled pens for subcutaneous injection, making it relatively straightforward for patients to use at home after receiving proper training from a healthcare professional.

• Starting dose: 2.5 mg once weekly (intended for dose escalation, not for ongoing maintenance). This starting dose is used to help the body adjust to the medication and minimize gastrointestinal side effects such as nausea.
• Maintenance doses: 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg once weekly. The dose is typically increased gradually, in consultation with a healthcare provider, to achieve optimal glycemic control while managing side effects.

The availability of multiple dose strengths allows for individualized treatment plans. Adjustments are usually made based on blood sugar monitoring, medication tolerability, and the presence or absence of side effects. Dose changes should only be made by a healthcare provider, who can assess your unique situation and guide you through the process safely.

Injection Schedule

Mounjaro should be injected once every seven days, at any time of day, with or without meals. The injection site can be the abdomen, thigh, or upper arm. Patients are typically advised to rotate sites to reduce irritation.

Administration is straightforward, but proper technique is important to maximize effectiveness and minimize discomfort. Before your first injection, your healthcare provider or pharmacist will demonstrate the process, explain how to prepare the pen, and show you how to dispose of needles safely. Some tips for successful self-injection include:

• Wash your hands and clean the injection site with an alcohol swab.
• Choose a different injection site each week to avoid irritation or scar tissue.
• Inject the medication subcutaneously (under the skin), not into muscle or vein.
• Follow the instructions provided in your medication’s packaging or by your healthcare provider.

Tracking Injections and Dosage Changes

Because Mounjaro therapy often involves gradual dose escalation, it’s helpful to log each dose, monitor for side effects, and note any changes in response. Digital trackers make this easier—see our complete guide to GLP-1 tracking apps for a comparison of privacy and features.

For example, you might use an app like Trimm to:

• Record the date, time, and site of each injection
• Log side effects such as nausea, vomiting, or injection site reactions
• Track blood sugar readings and how they change with dose adjustments
• Visualize trends in weight, energy, or appetite over time

Always consult your healthcare provider before making any changes to your dose or schedule. Never start, stop, or adjust medication on your own. Your safety and well-being are paramount, and open communication with your care team is vital for success.

Section 5: Mechanism of Action and Clinical Evidence

How Does Mounjaro Work?

Mounjaro (tirzepatide) is a first-in-class dual GIP and GLP-1 receptor agonist. It mimics the action of two naturally occurring hormones: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Together, these hormones help regulate blood sugar, reduce appetite, and slow gastric emptying.

• GIP/GLP-1 agonism: Enhances insulin secretion, suppresses glucagon, and decreases food intake. GIP and GLP-1 act synergistically to improve glucose-dependent insulin secretion from the pancreas, helping lower blood sugar after meals.
• Result: Lowered blood glucose and, as observed in studies, weight loss for many users. The slowing of gastric emptying can also promote a feeling of fullness and reduce overall calorie intake.

Unlike traditional diabetes medications, which typically target a single physiological pathway, tirzepatide’s dual action offers a broader and potentially more effective means of managing type 2 diabetes. By addressing both insulin resistance and appetite regulation, Mounjaro provides a multifaceted approach that has shown promise in real-world and clinical settings.

Clinical Trial Evidence Supporting Approval

The FDA’s decision to approve Mounjaro was based on data from nine clinical trials (SURPASS program), enrolling thousands of adults with type 2 diabetes. These studies compared Mounjaro to placebo and other diabetes medications, measuring changes in A1C (a marker of blood sugar control) and body weight over periods of up to 52 weeks.

• A1C reduction: Many participants achieved target A1C levels below 7%. In the most robust trials, Mounjaro reduced A1C by 1.6% to 2.4% from baseline, depending on the dose used and the comparator medication.
• Weight loss: Average weight loss varied by dose, with higher doses producing greater weight reduction, but this was a secondary endpoint for diabetes management—not a primary indication. Weight loss observed in studies varied depending on the dose and individual response.

For example, in one pivotal study, adults with type 2 diabetes receiving the 15 mg dose lost a significant amount of weight over 40-52 weeks, compared to placebo or other active comparators. These results were consistent across diverse patient populations, including those with varying levels of obesity, duration of diabetes, and prior use of other medications.

Importantly, the weight loss observed in these trials was a secondary benefit, not the primary outcome. The studies were not designed to answer questions about obesity treatment, which is why a separate program was required for Zepbound’s approval.

Additional Benefits and Considerations

While weight loss can be a significant benefit, the primary goal of Mounjaro is to improve blood sugar control in adults with type 2 diabetes. This distinction is key when considering insurance coverage, clinical goals, and FDA-approved uses. For more information about how to track side effects and progress on GLP-1s, see our guide to tracking GLP-1 side effects.

Other potential benefits of Mounjaro, observed in clinical trials, include reductions in blood pressure, improvements in cholesterol levels, and lower rates of hypoglycemia compared to some other diabetes drugs. However, these findings are considered exploratory, and further research is needed to determine their consistency and long-term clinical significance.

It’s also essential to recognize that individual results vary. Not every person will experience the same degree of blood sugar reduction or weight loss, and some may encounter side effects that limit the use of the medication. Tracking progress and communicating with your healthcare provider will help tailor your treatment for the best possible outcomes.

Section 6: FDA Safety Warnings and Label Updates

Boxed Warnings and Serious Risks

Mounjaro’s FDA label includes a boxed warning about the risk of thyroid C-cell tumors, based on findings in animal studies. It is not known if this risk occurs in humans, but the FDA advises against using Mounjaro in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

• Boxed warning: Risk of thyroid C-cell tumors; not approved for those with family history of certain thyroid cancers. The boxed warning is the FDA’s strongest warning, signaling the need for caution and awareness of potential risks.
• Other warnings: Pancreatitis, hypoglycemia (when used with other diabetes medications), gallbladder disease, serious allergic reactions, and acute kidney injury. Patients should be monitored for sudden, severe abdominal pain, persistent vomiting, or signs of dehydration, and should report these to their healthcare provider immediately.

While these risks are considered rare, they are serious. For example, pancreatitis (inflammation of the pancreas) can occur with GLP-1 receptor agonists, including Mounjaro. Symptoms that should prompt urgent medical attention include severe abdominal pain that may radiate to the back, especially if accompanied by vomiting or fever.

Recent FDA Label Updates

The FDA regularly updates Mounjaro’s prescribing information as new postmarketing data become available. Key updates include:

• Pregnancy exposure registry: Required to monitor outcomes if Mounjaro is used during pregnancy. The effects of Mounjaro on pregnant individuals and developing fetuses are not fully known, so its use is generally not recommended unless clearly needed.
• Pediatric studies: A postmarket commitment for Eli Lilly to complete safety and efficacy trials in children and adolescents by 2027. Until these results are available, Mounjaro remains contraindicated in anyone under 18 years of age.
• Not a controlled substance: Mounjaro is not classified as a controlled substance by the DEA. However, it should still be stored securely and kept out of reach of children and pets.
• Patient counseling updates: Health professionals are advised to educate patients about recognizing and managing side effects, particularly the symptoms of thyroid tumors, pancreatitis, and allergic reactions.

Monitoring and Reporting Side Effects

Patients are encouraged to report any side effects to their healthcare provider and the FDA’s MedWatch program. For practical guidance on logging side effects and tracking medication response, see our article on how to track side effects on GLP-1s. Using a tracker like Trimm can help you and your provider spot trends or issues early, supporting safer long-term use.

Common side effects experienced during clinical trials included nausea, vomiting, diarrhea, decreased appetite, constipation, and abdominal pain. Most of these effects were mild to moderate and tended to resolve over time or with dose adjustments. However, persistent or severe symptoms should always be discussed with a healthcare provider.

Here are some steps to take if you experience side effects:

• Keep a daily log of symptoms, including their timing and severity.
• Contact your healthcare provider if symptoms are severe, persistent, or interfere with daily life.
• Do not stop taking your medication without medical advice. Your provider can help adjust your dose or recommend strategies to manage side effects.
• Report serious or unexpected side effects to the FDA through the MedWatch program. This helps improve medication safety for everyone.

Conclusion

Mounjaro injection’s FDA approval in May 2022 was a breakthrough for adults with type 2 diabetes, offering both glycemic control and the added benefit of weight loss for many. However, as of January 2025, mounjaro injection FDA approval does not extend to weight loss or obesity treatment—those seeking tirzepatide for this purpose should look to Zepbound’s separate FDA approval. Dosages range from 2.5 mg to 15 mg weekly, with clinical evidence supporting its use for type 2 diabetes.

Safety remains a priority, with significant FDA boxed warnings and ongoing postmarket monitoring, especially regarding thyroid tumors and use in younger populations. Mounjaro is not approved for anyone under 18, and its use should always be guided by a healthcare professional. For those on a GLP-1 journey, tools like Trimm can help track medication, weight, and side effects—empowering you to engage in your care with confidence and clarity.

Managing type 2 diabetes is a journey that looks different for everyone. While medications like Mounjaro offer innovative new options, they are just one piece of the puzzle. Regular follow-up with your healthcare provider, attention to lifestyle choices, and self-advocacy are all important components of effective diabetes care. If you are considering or currently using Mounjaro, remember that your experience is unique and valid—progress, setbacks, and questions are all part of the process. With the right support and tools, you can make informed decisions and advocate for your health every step of the way.

FAQ

Q: When did the FDA approve Mounjaro injection?

A: The FDA approved Mounjaro injection (tirzepatide) on May 13, 2022, for use in adults with type 2 diabetes to improve glycemic control.

Q: Is Mounjaro FDA-approved for weight loss or obesity?

A: No, as of January 2025, Mounjaro is not FDA-approved for weight loss or obesity treatment. Its approval is for type 2 diabetes in adults. For weight loss, the FDA-approved tirzepatide product is Zepbound.

Q: What is the difference between Mounjaro and Zepbound?

A: Both contain tirzepatide. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is FDA-approved for weight management in adults with obesity or overweight with related conditions. The drugs are otherwise chemically identical but have different approved uses and insurance coverage criteria.

Q: Is Mounjaro approved for people under 18?

A: No. Mounjaro is not FDA-approved for anyone under 18. Pediatric studies are ongoing, with results expected by 2027.

Q: What dosage levels of Mounjaro are FDA-approved?

A: The FDA has approved Mounjaro injection in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg strengths, administered once weekly as a subcutaneous injection.

Q: Does Mounjaro have any FDA boxed warnings?

A: Yes. Mounjaro’s FDA label includes a boxed warning about the risk of thyroid C-cell tumors, and it should not be used by people with a personal or family history of certain thyroid cancers or related genetic syndromes.